GlassScriptPhysician profile
Cathy J Clary
NPI 1639177413
$4,389.95
in general payments reported to CMS, 2019-2025
25 companies · $28.96 in 2025
The $28.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $744 · 2021: $1,077 · 2022: $784 · 2023: $567 · 2024: $125 · 2025: $28.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $861.55 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $797.97 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $707.08 | 2019-2024 | Wegovy |
| Astellas Pharma US INC | $506.66 | 2019-2023 | Veozah |
| Pfizer INC. | $278.00 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $178.73 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $164.85 | 2019-2021 | |
| Amarin Pharma, INC. | $131.39 | 2020-2021 | |
| Abbott Laboratories | $126.52 | 2020-2024 | Freestyle Libre |
| Sunovion Pharmaceuticals INC. | $125.33 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.37 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $59.96 | 2019-2024 | Farxiga |
| Mylan Specialty L.P. | $59.06 | 2019-2022 | |
| Lilly USA, LLC | $44.66 | 2020-2022 | |
| Axonics, INC. | $44.27 | 2020-2023 | Axonics |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $30.67 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.82 | 2023 | Eliquis |
| Sumitomo Pharma America, INC. | $26.45 | 2023-2024 | Gemtesa |
| Esperion Therapeutics, INC. | $23.35 | 2021 | |
| Merck Sharp & Dohme LLC | $22.38 | 2019-2020 | |
| Seqirus USA INC | $19.62 | 2024 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $16.50 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.41 | 2022 | |
| Genentech USA, INC. | $15.17 | 2019 | |
| Eisai INC. | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Clary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.